SUBSTITUTED 2-ANILINOPYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS
申请人:CELLTECH THERAPEUTICS LIMITED
公开号:EP0862560B1
公开(公告)日:2003-04-02
US5958935A
申请人:——
公开号:US5958935A
公开(公告)日:1999-09-28
US6235746B1
申请人:——
公开号:US6235746B1
公开(公告)日:2001-05-22
[EN] MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE<br/>[FR] MODULATEURS DE LA VOIE DES RÉCEPTEURS DU FACTEUR DE CROISSANCE ÉPIDERMIQUE (EGFR) POUR UTILISATION DANS LE TRAITEMENT OU LA PRÉVENTION DE LA CONSOMMATION EXCESSIVE D'ALCOOL OU D'AUTRES DROGUES
申请人:UNIV CALIFORNIA
公开号:WO2009070328A1
公开(公告)日:2009-06-04
The present invention provides methods of using modulators of the epidermal growth factor receptor (EGFR) pathway for treatment or prevention of substance abuse such as alcohol abuse. The modulators include small molecule inhibitors such as Erlotinib (TARCEVA®, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- quinazolineamine) or a pharmaceutically acceptable salt, hydrate or prodrug thereof and Gefitinib [IRES S A®, N-(3 -chloro-4-fluoro-phenyl)-7-methoxy-6-(3 -morpholin-4- ylpropoxy)quinazolin-4-amine] or a pharmaceutically acceptable salt, hydrate or prodrug thereof and various macromolecular inhibitors of the EGFR pathway such as siRNAs and antibodies that target genes or proteins in the EGFR/ERK pathway such as one of the EGFR/ErbB protein or a homolog thereof.